日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Serviceability design charts for partially prestressed high-strength concrete girders

部分预应力高强混凝土梁的使用性能设计图表

Salem, Shady; Abu-Krisha, Mohamed; Hassan, Tarek; El-Hashimy, Tarek

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study

在患有中度或重度肝功能损害的受试者中,多次服用阿培利西布的药代动力学和安全性:一项 1 期、开放标签、平行组研究

Marbury, Thomas; El-Hashimy, Mona; Blumenstein, Lars; Letellier, Franck; Sengupta, Tirtha; Lorenzo, Sebastien; Preston, Richard Alfred

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

一项 I 期、开放标签、多中心研究,旨在评估布帕利西布联合替莫唑胺或联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤患者的疗效。

Wen, Patrick Yung; Rodon, Jordi A; Mason, Warren; Beck, Joseph T; DeGroot, John; Donnet, Valerie; Mills, David; El-Hashimy, Mona; Rosenthal, Mark

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

Buparlisib联合卡铂或洛莫司汀治疗复发性胶质母细胞瘤患者:一项Ib/II期、开放标签、多中心、随机研究

Rosenthal, Mark; Clement, Paul M; Campone, Mario; Gil-Gil, Miguel J; DeGroot, John; Chinot, Olivier; Idbaih, Ahmed; Gan, Hui; Raizer, Jeffrey; Wen, Patrick Yung; Pineda, Estela; Donnet, Valerie; Mills, David; El-Hashimy, Mona; Mason, Warren

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

BOLERO-2 研究揭示了绝经后激素受体阳性晚期乳腺癌患者依维莫司相关不良事件的发生率和时间进程:

Rugo, H S; Pritchard, K I; Gnant, M; Noguchi, S; Piccart, M; Hortobagyi, G; Baselga, J; Perez, A; Geberth, M; Csoszi, T; Chouinard, E; Srimuninnimit, V; Puttawibul, P; Eakle, J; Feng, W; Bauly, H; El-Hashimy, M; Taran, T; Burris, H A 3rd

Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2

在BOLERO-2研究中,依维莫司联合依西美坦作为HR⁺、HER2⁻晚期乳腺癌的一线治疗方案。

Beck, J Thaddeus; Hortobagyi, Gabriel N; Campone, Mario; Lebrun, Fabienne; Deleu, Ines; Rugo, Hope S; Pistilli, Barbara; Masuda, Norikazu; Hart, Lowell; Melichar, Bohuslav; Dakhil, Shaker; Geberth, Matthias; Nunzi, Martina; Heng, Daniel Y C; Brechenmacher, Thomas; El-Hashimy, Mona; Douma, Shyanne; Ringeisen, Francois; Piccart, Martine

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2

依维莫司对BOLERO-2研究中骨标志物水平和骨骼疾病进展的影响

Gnant, Michael; Baselga, Jose; Rugo, Hope S; Noguchi, Shinzaburo; Burris, Howard A; Piccart, Martine; Hortobagyi, Gabriel N; Eakle, Janice; Mukai, Hirofumi; Iwata, Hiroji; Geberth, Matthias; Hart, Lowell L; Hadji, Peyman; El-Hashimy, Mona; Rao, Shantha; Taran, Tetiana; Sahmoud, Tarek; Lebwohl, David; Campone, Mario; Pritchard, Kathleen I

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

一项针对既往接受过曲妥珠单抗和紫杉烷类药物治疗后病情进展的HER2过表达晚期乳腺癌患者的II期研究,评估依维莫司联合曲妥珠单抗和紫杉醇的疗效。

Hurvitz, Sara A; Dalenc, Florence; Campone, Mario; O'Regan, Ruth M; Tjan-Heijnen, Vivianne C; Gligorov, Joseph; Llombart, Antonio; Jhangiani, Haresh; Mirshahidi, Hamid R; Tan-Chiu, Elizabeth; Miao, Sara; El-Hashimy, Mona; Lincy, Jeremie; Taran, Tetiana; Soria, Jean-Charles; Sahmoud, Tarek; André, Fabrice

Strategies to improve the reporting of legal blindness in Massachusetts

马萨诸塞州改善法定盲人报告的策略

el-Hashimy, M M; Aubert, R E; Alich, K; Warram, J H; Harrigan, B A; Herman, W H